Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. (Q53899679)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. (English)

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

Koen van Besien

5

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

Fernando Cabanillas

16

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

1

object named as

Popat U

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

3

object named as

Saliba RM

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

Richard E Champlin

18

object named as

Champlin RE

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

10

object named as

Giralt S

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

7

object named as

Khouri IF

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

author name string

Anderlini P

4

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

Przepiorka D

6

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

Gajewski J

8

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

Claxton D

9

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

Rodriguez M

11

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

Romaguera J

12

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

Hagemeister F

13

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

Ha C

14

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

Cox J

15

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

Andersson BS

17

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

language of work or name

0 references

publication date

1 May 2004

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

Bone Marrow Transplantation

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

33

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

10

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

1015-1023

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704483

0 references

Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Twenty years of MOPP therapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Wide-field radiation therapy alone or with chemotherapy for Hodgkin's disease in relapse from combination chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Salvage Chemotherapy with ABVD in MOPP-Resistant Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Autologous bone marrow transplantation for patients with relapsed hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

The Analysis of Failure Times in the Presence of Competing Risks

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Should high risk patients with Hodgkin's disease be singled out for heavier therapeutic regimens while low risk patients are spared such therapies?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Increased risk of second cancers in managing Hodgkins disease: the 20-year Leiden experience.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

21 January 2018

Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended mantle radiation therapy for pathologic stage I and II Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination Chemotherapy and Survival in Advanced Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Hodgkin's disease: Combination chemotherapy for relapse following radical radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiation therapy salvage of Hodgkin's disease following chemotherapy failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage radiotherapy in recurrent Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Ten-year nodular sclerosis Hodgkin's disease and second malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of second cancers after treatment for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704483

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1704483

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15048145

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53899679&oldid=1810054711"